Xeltis, a clinical-stage medtech company developing living implants that enable the body to restore cardiovascular function, has raised €32 million in a Series D2 equity fundraise. The fundraising has been backed by a syndicate of current and new investors, including Grand Pharma, DaVita Venture Group, EQT Life Sciences, Invest-NL, and other international investors. This fundraising round will enable Xeltis to progress its key clinical programs into pivotal trials, as it aims to give patients around the world access to the world’s most advanced restorative cardiovascular devices.
Xeltis’ breakthrough technology is focused on restoring the body’s natural cardiovascular functions, with numerous potential applications. The Company’s proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer-based material that triggers the body’s natural healing response to regenerate the patient’s own tissue around it, forming new, living, and long-lasting vessels and valves. Xeltis’ most advanced program, aXess, is a vascular access graft for patients with chronic kidney disease (CKD) requiring hemodialysis. Preliminary in-human clinical trial data from the Company’s ongoing aXess studies have been very encouraging. The Company is also pursuing clinical programs in pulmonary valve replacement and coronary artery bypass grafts.
Read more at Brainport Eindhoven.
